When will Orforglipron be approved?

The experimental pill for chronic weight management and type 2 diabetes called orforglipron is in development from Eli Lilly, the same company that manufactures the weight-loss injection Zepbound (tirzepatide). While Zepbound is a once-weekly injection, orforglipron is designed to be taken by mouth once a day, without any food or liquid restrictions.

After successful Phase 2 trials for obesity and type 2 diabetes, orforglipron is currently in several Phase 3 trials further testing its safety and efficacy. Eli Lilly is expected to seek approval for weight loss by the end of this year and type 2 diabetes in 2026. It could possibly be available shortly after if approved.